Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 20/20 | 1.00 |
| ▸ | BCL2 | P10415 | 2/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205726 | 1.00 | MCL1 (1.00) | MCL1BCL2ALBBCL2L1 | |
| SCHEMBL29928106 | 0.90 | MCL1 (0.82) | MCL1BCL2ALBBCL2L1 | |
| SCHEMBL15622598 | 0.89 | MCL1 (0.80) | MCL1BCL2ALBBCL2L1 | |
| SCHEMBL15621978 | 0.88 | MCL1 (0.78) | MCL1BCL2ALBBCL2L1 | |
| SCHEMBL2204330 | 0.88 | MCL1 (0.78) | MCL1BCL2ALBBCL2L1 | |
| SCHEMBL15622733 | 0.88 | MCL1 (0.85) | MCL1BCL2ALBBCL2L1 | |
| SCHEMBL29928296 | 0.88 | MCL1 (1.00) | MCL1BCL2ALBBCL2L1 | |
| SCHEMBL2203925 | 0.88 | MCL1 (0.78) | MCL1BCL2ALBBCL2L1 | |
| SCHEMBL15622564 | 0.87 | MCL1 (1.00) | MCL1BCL2ALBBCL2L1 | |
| SCHEMBL2206136 | 0.87 | MCL1 (0.77) | MCL1BCL2ALBBCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492358-B1 | Macrocyclic indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11478451-B1 | Macrocyclic chlorine substituted indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-25 | — | — | US | disclosed |
| US-11447504-B2 | Macrocyclic chlorine substituted indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-20 | — | — | US | disclosed |
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492358-B1 | Macrocyclic indole derivatives | CCND2, CCNT2, IDO1 | MCL1 54/4885BCL2 624/4885ALB 2929/4885 |
| US-11447504-B2 | Macrocyclic chlorine substituted indole derivatives | CCNT2, CCNL2, CCND2 | MCL1 26/4885BCL2 430/4885ALB 2966/4885 |
| US-11478451-B1 | Macrocyclic chlorine substituted indole derivatives | CCNT2, CCNL2, CCND2 | MCL1 26/4885BCL2 430/4885ALB 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.